A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(17 sites)

China

Beijing Tsinghua Changgung Hospital, Beijing

Peking University People's Hospital, Beijing

Xiangya Hospital Of Gentral South University, Changsha

Guangdong Provincial People's Hospital, Guangzhou

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

The First Affiliated Hospital Zhejiang University School Of Medicine, Hangzhou

The Second Hospital of Anhui Medical University, Hefei

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

Jiangxi Provincial People's Hospital, Nanchang

The First Affiliated Hospital of Nanchang University, Nanchang

Jiangsu Province Hospital, Nanjing

Zhongdong Hospital Southeast University, Nanjing

Shanghai General Hospital, Shanghai

Renmin Hospital Of Wuhan University, Wuhan

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an

The First Affiliated Hospital Of Xiamen University, Xiamen

Su Bei People's Hospital, Yangzhou